Health Care·Biotechnology·$79.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.83 | N/A | +5.01% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.83 | N/A | +5.01% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, indicating a commitment to pipeline development. However, they did not provide specific guidance for future performance.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
Regeneron Pharmaceuticals reported better-than-expected earnings per share, but the stock fell by 6.29% following the announcement. Investors may have reacted negatively due to the lack of revenue details and guidance. The cautious tone from management suggests a focus on long-term growth rather than immediate financial targets.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CREDICORP LTD
Feb 8, 2016